Search

Your search keyword '"Bernstein, Jonine"' showing total 341 results
Start Over Author "Bernstein, Jonine" Language english
341 results on '"Bernstein, Jonine"'

3. First international workshop of the ATM and cancer risk group (4-5 December 2019)

Author

Lesueur, Fabienne, Easton, Douglas F., Renault, Anne-Laure, Tavtigian, Sean V., Bernstein, Jonine L., Kote-Jarai, Zsofia, Eeles, Rosalind A., Plaseska-Karanfia, Dijana, Feliubadaló, Lidia, Arun, Banu, Herold, Natalie, Versmold, Beatrix, Schmutzler, Rita Katharina, Nguyen-Dumont, Tú, Southey, Melissa C., Dorling, Leila, Dunning, Alison M., Ghiorzo, Paola, Dalmasso, Bruna Samia, Cavaciuti, Eve, Le Gal, Dorothée, Roberts, Nicholas J., Dominguez-Valentin, Mev, Rookus, Matti, Taylor, Alexander M. R., Goldstein, Alisa M., Goldgar, David E., Stoppa-Lyonnet, Dominique, and Andrieu, Nadine

Published
2022
Full Text
View/download PDF

6. Recommendations on statistical approaches to account for dose uncertainties in radiation epidemiologic risk models.

Author

Bellamy, Michael B., Bernstein, Jonine L., Cullings, Harry M., French, Benjamin, Grogan, Helen A., Held, Kathryn D., Little, Mark P., and Tekwe, Carmen D.

Subjects
*RADIATION doses, *RADIATION dosimetry
Abstract

AbstractPurposeConclusionsEpidemiological studies of stochastic radiation health effects such as cancer, meant to estimate risks of the adverse effects as a function of radiation dose, depend largely on estimates of the radiation doses received by the exposed group under study. Those estimates are based on dosimetry that always has uncertainty, which often can be quite substantial. Studies that do not incorporate statistical methods to correct for dosimetric uncertainty may produce biased estimates of risk and incorrect confidence bounds on those estimates. This paper reviews commonly used statistical methods to correct radiation risk regressions for dosimetric uncertainty, with emphasis on some newer methods. We begin by describing the types of dose uncertainty that may occur, including those in which an uncertain value is shared by part or all of a cohort, and then demonstrate how these sources of uncertainty arise in radiation dosimetry. We briefly describe the effects of different types of dosimetric uncertainty on risk estimates, followed by a description of each method of adjusting for the uncertainty.Each of the method has strengths and weaknesses, and some methods have limited applicability. We describe the types of uncertainty to which each method can be applied and its pros and cons. Finally, we provide summary recommendations and touch briefly on suggestions for further research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer: The WECARE Study

Author

Bernstein, Jonine L., Capanu, Marinela, Orlow, Irene, Robson, Mark, Olsen, Jørgen H., Malone, Kathleen E., Stovall, Marilyn, Blackmore, Kristina, Harris, Irene, Langballe, Rikke, O’Brien, Cecilia, Weathers, Rita, West, Michele, Hunter, Lisa, Goldstein, Judy, Ramos, Elaine, Carlson, Lauren E., Watt, Gordon P., Tonorezos, Emily S., Chow, Eric J., Yu, Anthony F., Woods, Meghan, Lynch, Charles F., John, Esther M., Mellemkjӕr, Lene, Brooks, Jennifer D., Knight, Julia A., Reiner, Anne S., Liang, Xiaolin, Smith, Susan A., Bernstein, Leslie, Dauer, Lawrence T., Cerviño, Laura I., Howell, Rebecca M., Shore, Roy E., and Boice, John D., Jr.

Published
2021
Full Text
View/download PDF

8. A case-control study of the joint effect of reproductive factors and radiation treatment for first breast cancer and risk of contralateral breast cancer in the WECARE study

Author

Bernstein, Jonine L., Brooks, Jennifer D., Boice, John D., Jr., Shore, Roy E., Reiner, Anne S., Smith, Susan A., Bernstein, Leslie, Knight, Julia A., Lynch, Charles F., John, Esther M., Malone, Kathleen E., Mellemkjaer, Lene, Langballe, Rikke, Liang, Xiaolin, Woods, Meghan, Tischkowitz, Marc, Concannon, Patrick, and Stram, Daniel O.

Published
2020
Full Text
View/download PDF

9. Association of breast cancer with quantitative mammographic density measures for women receiving contrast-enhanced mammography.

Author

Watt, Gordon P, Keshavamurthy, Krishna N, Nguyen, Tuong L, Lobbes, Marc B I, Jochelson, Maxine S, Sung, Janice S, Moskowitz, Chaya S, Patel, Prusha, Liang, Xiaolin, Woods, Meghan, Hopper, John L, Pike, Malcolm C, and Bernstein, Jonine L

Subjects
BREAST cancer, MAMMOGRAMS
Abstract

Women with high mammographic density have an increased risk of breast cancer. They may be offered contrast-enhanced mammography to improve breast cancer screening performance. Using a cohort of women receiving contrast-enhanced mammography, we evaluated whether conventional and modified mammographic density measures were associated with breast cancer. Sixty-six patients with newly diagnosed unilateral breast cancer were frequency matched on the basis of age to 133 cancer-free control individuals. On low-energy craniocaudal contrast-enhanced mammograms (equivalent to standard mammograms), we measured quantitative mammographic density using CUMULUS software at the conventional intensity threshold ("Cumulus") and higher-than-conventional thresholds ("Altocumulus," "Cirrocumulus"). The measures were standardized to enable estimation of odds ratio per adjusted standard deviation (OPERA). In multivariable logistic regression of case-control status, only the highest-intensity measure (Cirrocumulus) was statistically significantly associated with breast cancer (OPERA = 1.40, 95% confidence interval = 1.04 to 1.89). Conventional Cumulus did not contribute to model fit. For women receiving contrast-enhanced mammography, Cirrocumulus mammographic density may better predict breast cancer than conventional quantitative mammographic density. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists

Author

Bergom, Carmen, West, Catharine M., Higginson, Daniel S., Abazeed, Mohamed E., Arun, Banu, Bentzen, Soren M., Bernstein, Jonine L., Evans, Jaden D., Gerber, Naamit K., Kerns, Sarah L., Keen, Judy, Litton, Jennifer K., Reiner, Anne S., Riaz, Nadeem, Rosenstein, Barry S., Sawakuchi, Gabriel O., Shaitelman, Simona F., Powell, Simon N., and Woodward, Wendy A.

Published
2019
Full Text
View/download PDF

15. Trends in Radiation Dose to the Contralateral Breast During Breast Cancer Radiation Therapy.

Author

Watt, Gordon P., Smith, Susan A., Howell, Rebecca M., Pérez-Andújar, Angélica, Reiner, Ann S., Cerviño, Laura, McCormick, Beryl, Hess, Daniela, Knight, Julia A., Malone, Kathleen E., John, Esther M., Bernstein, Leslie, Lynch, Charles F., Mellemkjær, Lene, Shore, Roy E., Liang, Xiaolin, Woods, Meghan, Boice Jr., John D., Dauer, Lawrence T., and Bernstein, Jonine L.

Subjects
BREAST, RADIATION doses, BREAST cancer, CANCER treatment, CANCER radiotherapy, BODY mass index
Abstract

Over 4 million survivors of breast cancer live in the United States, 35% of whom were treated before 2009. Approximately half of patients with breast cancer receive radiation therapy, which exposes the untreated contralateral breast to radiation and increases the risk of a subsequent contralateral breast cancer (CBC). Radiation oncology has strived to reduce unwanted radiation dose, but it is unknown whether a corresponding decline in actual dose received to the untreated contralateral breast has occurred. The purpose of this study was to evaluate trends in unwanted contralateral breast radiation dose to inform risk assessment of second primary cancer in the contralateral breast for long-term survivors of breast cancer. Individually estimated radiation absorbed doses to the four quadrants and areola central area of the contralateral breast were estimated for 2,132 women treated with radiation therapy for local/regional breast cancers at age <55 years diagnosed between 1985 and 2008. The two inner quadrant doses and two outer quadrant doses were averaged. Trends in dose to each of the three areas of the contralateral breast were evaluated in multivariable models. The population impact of reducing contralateral breast dose on the incidence of radiation-associated CBC was assessed by estimating population attributable risk fraction (PAR) in a multivariable model. The median dose to the inner quadrants of the contralateral breast was 1.70 Gy; to the areola, 1.20 Gy; and to the outer quadrants, 0.72 Gy. Ninety-two percent of patients received ≥1 Gy to the inner quadrants. For each calendar year of diagnosis, dose declined significantly for each location, most rapidly for the inner quadrants (0.04 Gy/year). Declines in dose were similar across subgroups defined by age at diagnosis and body mass index. The PAR for CBC due to radiation exposure >1 Gy for women <40 years of age was 17%. Radiation dose-reduction measures have reduced dose to the contralateral breast during breast radiation therapy. Reducing the dose to the contralateral breast to <1 Gy could prevent an estimated 17% of subsequent radiation-associated CBCs for women treated under 40 years of age. These dose estimates inform CBC surveillance for the growing number of breast cancer survivors who received radiation therapy as young women in recent decades. Continued reductions in dose to the contralateral breast could further reduce the incidence of radiation-associated CBC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case–control study

Author

Berntsson, Shala G., Merrell, Ryan T., Amirian, E. Susan, Armstrong, Georgina N., Lachance, Daniel, Smits, Anja, Zhou, Renke, Jacobs, Daniel I., Wrensch, Margaret R., Olson, Sara H., Il’yasova, Dora, Claus, Elizabeth B., Barnholtz-Sloan, Jill S., Schildkraut, Joellen, Sadetzki, Siegal, Johansen, Christoffer, Houlston, Richard S., Jenkins, Robert B., Bernstein, Jonine L., Lai, Rose, Shete, Sanjay, Amos, Christopher I., Bondy, Melissa L., and Melin, Beatrice S.

Published
2018
Full Text
View/download PDF

17. Influence of obesity-related risk factors in the aetiology of glioma

Author

Disney-Hogg, Linden, Sud, Amit, Law, Philip J., Cornish, Alex J., Kinnersley, Ben, Ostrom, Quinn T., Labreche, Karim, Eckel-Passow, Jeanette E., Armstrong, Georgina N., Claus, Elizabeth B., Il’yasova, Dora, Schildkraut, Joellen, Barnholtz-Sloan, Jill S., Olson, Sara H., Bernstein, Jonine L., Lai, Rose K., Swerdlow, Anthony J., Simon, Matthias, Hoffmann, Per, Nöthen, Markus M., Jöckel, Karl-Heinz, Chanock, Stephen, Rajaraman, Preetha, Johansen, Christoffer, Jenkins, Robert B., Melin, Beatrice S., Wrensch, Margaret R., Sanson, Marc, Bondy, Melissa L., and Houlston, Richard S.

Published
2018
Full Text
View/download PDF

18. Publisher Correction: Mendelian randomisation study of the relationship between vitamin D and risk of glioma

Author

Takahashi, Hannah, Cornish, Alex J., Sud, Amit, Law, Philip J., Kinnersley, Ben, Ostrom, Quinn T., Labreche, Karim, Eckel-Passow, Jeanette E., Armstrong, Georgina N., Claus, Elizabeth B., Il’yasova, Dora, Schildkraut, Joellen, Barnholtz-Sloan, Jill S., Olson, Sara H., Bernstein, Jonine L., Lai, Rose K., Schoemaker, Minouk J., Simon, Matthias, Hoffmann, Per, Nöthen, Markus M., Jöckel, Karl-Heinz, Chanock, Stephen, Rajaraman, Preetha, Johansen, Christoffer, Jenkins, Robert B., Melin, Beatrice S., Wrensch, Margaret R., Sanson, Marc, Bondy, Melissa L., Turnbull, Clare, and Houlston, Richard S.

Published
2019
Full Text
View/download PDF

19. Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study

Author

Robson, Mark E., Reiner, Anne S., Brooks, Jennifer D., Concannon, Patrick J., John, Esther M., Mellemkjaer, Lene, Bernstein, Leslie, Malone, Kathleen E., Knight, Julia A., Lynch, Charles F., Woods, Meghan, Liang, Xiaolin, Haile, Robert W., Duggan, David J., Shore, Roy E., Smith, Susan A., Thomas, Duncan C., Stram, Daniel O., and Bernstein, Jonine L.

Published
2017
Full Text
View/download PDF

21. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors

Author

Melin, Beatrice S, Barnholtz-Sloan, Jill S, Wrensch, Margaret R, Johansen, Christoffer, Il'yasova, Dora, Kinnersley, Ben, Ostrom, Quinn T, Labreche, Karim, Chen, Yanwen, Armstrong, Georgina, Liu, Yanhong, Eckel-Passow, Jeanette E, Decker, Paul A, Labussière, Marianne, Idbaih, Ahmed, Hoang-Xuan, Khe, Di Stefano, Anna-Luisa, Mokhtari, Karima, Delattre, Jean-Yves, Broderick, Peter, Galan, Pilar, Gousias, Konstantinos, Schramm, Johannes, Schoemaker, Minouk J, Fleming, Sarah J, Herms, Stefan, Heilmann, Stefanie, Nöthen, Markus M, Wichmann, Heinz-Erich, Schreiber, Stefan, Swerdlow, Anthony, Lathrop, Mark, Simon, Matthias, Sanson, Marc, Andersson, Ulrika, Rajaraman, Preetha, Chanock, Stephen, Linet, Martha, Wang, Zhaoming, Yeager, Meredith, Wiencke, John K, Hansen, Helen, McCoy, Lucie, Rice, Terri, Kosel, Matthew L, Sicotte, Hugues, Amos, Christopher I, Bernstein, Jonine L, Davis, Faith, Lachance, Dan, Lau, Ching, Merrell, Ryan T, Shildkraut, Joellen, Ali-Osman, Francis, Sadetzki, Siegal, Scheurer, Michael, Shete, Sanjay, Lai, Rose K, Claus, Elizabeth B, Olson, Sara H, Jenkins, Robert B, Houlston, Richard S, and Bondy, Melissa L

Published
2017
Full Text
View/download PDF

22. The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

Author

Lakeman, Inge M. M., Van Den Broek, Alexandra J., Vos, Juliën A. M., Barnes, Daniel R., Adlard, Julian, Andrulis, Irene L., Arason, Adalgeir, Arnold, Norbert, Arun, Banu K., Balmaña, Judith, Barrowdale, Daniel, Giraud, Sophie, Golmard, Lisa, Hake, Christopher R., Houdayer, Claude, Risch, Harvey A., Lasset, Christine, Laurent, Maïté, Spurdle, Amanda B., Hooning, Maartje J., Hopper, John L., Kets, Carolien M., Leroux, Dominique, Longy, Michel, Mari, Véronique, Mazoyer, Sylvie, Mebirouk, Noura, Mortemousque, Isabelle, Blok, Marinus J., Prieur, Fabienne, Hamann, Ute, Pujol, Pascal, Konstantopoulou, Irene, Heemskerk Gerritsen, Bernadette A. M., Isaacs, Claudine, Saule, Claire, Piedmonte, Marion, Schuster, Helene, Sevenet, Nicolas, Sobol, Hagay, Sokolowska, Johanna, Gómez Garcia, Encarna B., Venat Bouvet, Laurence, Claes, Kathleen B. M., Ahmed, Munaza, Teixeira, Manuel R., Barwell, Julian, Brady, Angela, Izatt, Louise, Hogervorst, Frans B. L., Brennan, Paul, Harrington, Patricia A., Henderson, Alex, Hodgson, Shirley, Kwong, Ava, Borg, Ake, Kennedy, M. John, Porteous, Mary E., Rogers, Mark T., Side, Lucy E., Snape, Katie, Walker, Lisa, Collée, J. Margriet, Jakubowska, Anna, Couch, Fergus J., Hahnen, Eric, Daly, Mary B., Dennis, Joe, Teo, Soo Hwang, Jensen, Uffe Birk, Rantala, Johanna, Dhawan, Mallika, Benitez, Javier, Domchek, Susan M., Eeles, Ros, Engel, Christoph, Legrand, Clémentine, Evans, D. Gareth, James, Paul A., Feliubadaló i Elorza, Maria Lídia, Teulé-Vega, Àlex, Foretova, Lenka, Castera, Laurent, Friedman, Eitan, Frost, Debra, Rennert, Gad, Ganz, Patricia A., Leslie, Goska, Garber, Judy, Hulick, Peter J., Imyanitov, Evgeny N., Glendon, Gord, Thomassen, Mads, Janavicius, Ramunas, Mulligan, Anna Marie, Hollestelle, Antoinette, Jager, Agnes, Koppert, Linetta B., Cook, Jackie, Koudijs, Marco, Kriege, Mieke, Meijers Heijboer, Hanne E. J., Schmutzler, Rita K., Mensenkamp, Arjen R., Dunning, Alison M., Mooij, Thea M., Oosterwijk, Jan C., Caux Moncoutier, Virginie, Singer, Christian F., Berthet, Pascaline, Caldés, Trinidad, Van den Ouweland, Ans M. W., Van der Baan, Frederieke H., Van der Hout, Annemieke H., Van der Kolk, Lizet E., Van der Luijt, Rob B., Thull, Darcy L., Van Deurzen, Carolien H. M., Sharma, Priyanka, Van Doorn, Helena C., Bignon, Yves Jean, Colas, Chrystelle, Van Engelen, Klaartje, Brewer, Carole, Van Hest, Liselotte P., Van Os, Theo A. M., Caligo, Maria A., Verhoef, Senno, Tischkowitz, Marc, Vogel, Maartje J., Wijnen, Juul T., Lalloo, Fiona, Beesley, Jonathan, Fox, Stephen, Collonge Rame, Marie Agnès, Simard, Jacques, Holland, Helene, Jiao, Yue, John, Esther M., Joseph, Vijai, Gerdes, Anne Marie, Karlan, Beth Y., Lesueur, Fabienne, Loud, Jennifer T., Lubiński, Jan, Manoukian, Siranoush, Mcguffog, Lesley, Miller, Austin, Coupier, Isabelle, Gomes, Denise Molina, Barouk Simonet, Emmanuelle, Montagna, Marco, Miller, Clare, Elan, Camille, Davidson, Rosemarie, Mouret Fourme, Emmanuelle, Gayther, Simon A., Nathanson, Katherine L., Neuhausen, Susan L., Nevanlinna, Heli, Yie, Joanne Ngeow Yuen, Pauw, Antoine de, Olah, Edith, Morrison, Patrick J., Olopade, Olufunmilayo I., Van Asperen, Christi J., Park, Sue K., Parsons, Michael T., Donaldson, Alan, Belotti, Muriel, Peterlongo, Paolo, Stadler, Zsofia, Stoppa Lyonnet, Dominique, Sutter, Christian, Ong, Kai Ren, Delnatte, Capucine, Tan, Yen Yen, Toland, Amanda E., Tung, Nadine, Van Rensburg, Elizabeth J., Vega, Ana, Wappenschmidt, Barbara, Devilee, Peter, Eason, Jacqueline, Chung, Wendy K., Bernstein, Jonine L., Offit, Kenneth, Aalfs, Cora M., Hanson, Helen, Godwin, Andrew K., Easton, Douglas F., Bonadona, Valérie, Rookus, Matti A., Chenevix-Trench, Georgia, Antoniou, Antonis C., O’shaughnessy Kirwan, Aoife, Robson, Mark, Eccles, Diana M., Schmidt, Marjanka K., Adank, Muriel A., Gemo Study Collaborators, Phillips, Kelly Anne, Embrace Collaborators, Ocgn Investigators, Goldgar, David E., Hebon Investigators, Perkins, Jo, Kconfab Investigators, Bressac de Paillerets, Brigitte, Buecher, Bruno, Caputo, Sandrine, Ausems, Margreet G. E. M., Gregory, Helen, Caron, Olivier, Faivre, Laurence, Fert Ferrer, Sandra, Gauthier Villars, Marion, Radice, Paolo, Gesta, Paul, Clinical Genetics, Medical Oncology, Surgery, Pathology, Gynecological Oncology, Schmidt, Marjanka K. [0000-0002-2228-429X], Apollo - University of Cambridge Repository, Targeted Gynaecologic Oncology (TARGON), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Schmidt, Marjanka K [0000-0002-2228-429X], HUS Gynecology and Obstetrics, Department of Obstetrics and Gynecology, Institut Català de la Salut, [Lakeman IMM] Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. [van den Broek AJ, Vos JAM] Division of Molecular Pathology, The Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. [Barnes DR] Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. [Adlard J] Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, UK. [Andrulis IL] Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada. Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. [Balmaña J] Hereditary cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Pediatric surgery, Human genetics, Amsterdam Neuroscience - Complex Trait Genetics, CCA - Cancer biology and immunology, Epidemiology and Data Science, Human Genetics, ARD - Amsterdam Reproduction and Development, APH - Personalized Medicine, APH - Quality of Care, Chapel Allerton Hospital, University of Leeds, Departments of Molecular Genetics and Laboratory Medicine and Pathobiology, University of Toronto-Cancer Care Ontario, Reykjavík University, Division of Oncology, Department of Gynaecology and Obstetrics, University Hospital Schleswig–Holstein, The University of Texas M.D. Anderson Cancer Center [Houston], Unitat d'Alt Risc i Prevenció del Càncer, Vall d'Hebron University Hospital [Barcelona], University of Cambridge [UK] (CAM), Group of Human Genetics, Human Cancer Genetics Programme, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Department of Oncology, Clinical Sciences, Lund University [Lund]-Skåne University Hospital, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Section of Genetic Oncology, University of Pisa - Università di Pisa, Columbia University [New York], Ghent University Hospital, Department of Clinical Genetics, Erasmus University Medical Center [Rotterdam] (Erasmus MC)-Family Cancer Clinic, Department of Laboratory Medicine and Pathology, Mayo Clinic, Division of Population Science, Fox Chase Cancer Center, Institut Curie [Paris], Mines Paris - PSL (École nationale supérieure des mines de Paris), Université Paris sciences et lettres (PSL), CHU Grenoble, CHI Poissy-Saint-Germain, Unité de génétique et biologie des cancers (U830), Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud]), RS: GROW - R4 - Reproductive and Perinatal Medicine, MUMC+: DA KG Lab Centraal Lab (9), MUMC+: DA KG Polikliniek (9), and Klinische Genetica

Subjects
0301 basic medicine, Percentile, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Susceptibility::Genetic Predisposition to Disease [DISEASES], Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], SUSCEPTIBILITY ALLELES, Diàtesi, FAMILIES, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], MESH: BRCA2 Protein, Breast cancer, 0302 clinical medicine, MESH: Risk Factors, Risk Factors, Other subheadings::/diagnosis [Other subheadings], Medicine and Health Sciences, Medicine, Mama - Càncer - Diagnòstic, Family history, skin and connective tissue diseases, Genetics (clinical), MESH: Heterozygote, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Factors de risc en les malalties, BRCA1 Protein, Hazard ratio, MESH: Genetic Predisposition to Disease, 1184 Genetics, developmental biology, physiology, article, OVARIAN, BRCA2 Protein/genetics, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], 3. Good health, 030220 oncology & carcinogenesis, Female, Malalties congènites, Adult, Heterozygote, medicine.medical_specialty, MESH: Mutation, Risk factors in diseases, Otros calificadores::/diagnóstico [Otros calificadores], Breast Neoplasms, Context (language use), MUTATION CARRIERS, Càncer de mama, afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::susceptibilidad a enfermedades::predisposición genética a la enfermedad [ENFERMEDADES], 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Humans, Genetic Predisposition to Disease, MESH: BRCA1 Protein, Retrospective Studies, BRCA2 Protein, MESH: Humans, business.industry, Proportional hazards model, CONSORTIUM, Breast Neoplasms/diagnosis, MESH: Adult, MESH: Retrospective Studies, Retrospective cohort study, medicine.disease, Confidence interval, 030104 developmental biology, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Mutation, BRCA1 Protein/genetics, 3111 Biomedicine, business, MESH: Female, MESH: Breast Neoplasms
Abstract

Predicció de risc de càncer de mama; Dones europees; Variant patògena heterozigota Predicción del riesgo de cáncer de mama; Mujeres europeas; Variante patógena heterocigota Breast cancer risk prediction; European women; Heterozygous pathogenic variant Purpose To evaluate the association between a previously published 313 variant–based breast cancer (BC) polygenic risk score (PRS313) and contralateral breast cancer (CBC) risk, in BRCA1 and BRCA2 pathogenic variant heterozygotes. Methods We included women of European ancestry with a prevalent first primary invasive BC (BRCA1 = 6,591 with 1,402 prevalent CBC cases; BRCA2 = 4,208 with 647 prevalent CBC cases) from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), a large international retrospective series. Cox regression analysis was performed to assess the association between overall and ER-specific PRS313 and CBC risk. Results For BRCA1 heterozygotes the estrogen receptor (ER)-negative PRS313 showed the largest association with CBC risk, hazard ratio (HR) per SD = 1.12, 95% confidence interval (CI) (1.06–1.18), C-index = 0.53; for BRCA2 heterozygotes, this was the ER-positive PRS313, HR = 1.15, 95% CI (1.07–1.25), C-index = 0.57. Adjusting for family history, age at diagnosis, treatment, or pathological characteristics for the first BC did not change association effect sizes. For women developing first BC

Published
2021

24. Contralateral breast cancers: Independent cancers or metastases?

Author

Begg, Colin B., Ostrovnaya, Irina, Geyer, Felipe C., Papanastasiou, Anastasios D., Ng, Charlotte K.Y., Sakr, Rita A., Bernstein, Jonine L., Burke, Kathleen A., King, Tari A., Piscuoglio, Salvatore, Mauguen, Audrey, Orlow, Irene, Weigelt, Britta, Seshan, Venkatraman E., Morrow, Monica, and Reis‐Filho, Jorge S.

Published
2018
Full Text
View/download PDF

26. Impact of atopy on risk of glioma: a Mendelian randomisation study

Author

Disney-Hogg, Linden, Cornish, Alex J., Sud, Amit, Law, Philip J., Kinnersley, Ben, Jacobs, Daniel I., Ostrom, Quinn T., Labreche, Karim, Eckel-Passow, Jeanette E., Armstrong, Georgina N., Claus, Elizabeth B., Il’yasova, Dora, Schildkraut, Joellen, Barnholtz-Sloan, Jill S., Olson, Sara H., Bernstein, Jonine L., Lai, Rose K., Schoemaker, Minouk J., Simon, Matthias, Hoffmann, Per, Nöthen, Markus M., Jöckel, Karl-Heinz, Chanock, Stephen, Rajaraman, Preetha, Johansen, Christoffer, Jenkins, Robert B., Melin, Beatrice S., Wrensch, Margaret R., Sanson, Marc, Bondy, Melissa L., and Houlston, Richard S.

Published
2018
Full Text
View/download PDF

27. Mendelian randomisation study of the relationship between vitamin D and risk of glioma

Author

Takahashi, Hannah, Cornish, Alex J., Sud, Amit, Law, Philip J., Kinnersley, Ben, Ostrom, Quinn T., Labreche, Karim, Eckel-Passow, Jeanette E., Armstrong, Georgina N., Claus, Elizabeth B., Il’yasova, Dora, Schildkraut, Joellen, Barnholtz-Sloan, Jill S., Olson, Sara H., Bernstein, Jonine L., Lai, Rose K., Schoemaker, Minouk J., Simon, Matthias, Hoffmann, Per, Nöthen, Markus M., Jöckel, Karl-Heinz, Chanock, Stephen, Rajaraman, Preetha, Johansen, Christoffer, Jenkins, Robert B., Melin, Beatrice S., Wrensch, Margaret R., Sanson, Marc, Bondy, Melissa L., Turnbull, Clare, and Houlston, Richard S.

Published
2018
Full Text
View/download PDF

29. Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case–control study of contralateral breast cancer risk in the WECARE Study

Author

The WECARE Study Collaborative Group, Brooks, Jennifer D., Teraoka, Sharon N., Bernstein, Leslie, Mellemkjær, Lene, Malone, Kathleen E., Lynch, Charles F., Haile, Robert W., Concannon, Patrick, Reiner, Anne S., Duggan, David J., Schiermeyer, Katherine, Bernstein, Jonine L., and Figueiredo, Jane C.

Published
2013

32. Radiation disasters – long term consequences: reflections and summary of a recent symposium.

Author

Burtt, Julie J., Akiba, Suminori, Bazyka, Dimitry, Coleman, C. Norman, Hatch, Maureen, and Bernstein, Jonine L.

Subjects
THYROID cancer, THYROID diseases, RADIATION, NUCLEAR power plant accidents, SENDAI Earthquake, Japan, 2011, MEDICAL sciences
Abstract

A cohort study of thyroid cancer and other thyroid diseases after the chornobyl accident: thyroid cancer in Ukraine detected during first screening. A significant excess of multiple myeloma incidence [standardized incidence rate (SIR) 1.61; 95% confidence interval (CI) 1.01-2.21], thyroid cancer (SIR 4.18, 95% CI 3.76-4.59), female breast cancer (SIR1.57 CI 1.40-1.73), and all cancers combined (SIR 1.07; 95% CI 1.05-1.09) was registered (Bazyka et al. [8]). Thoughts and substantial progress of the radiation research field regarding the Fukushima nuc... The knowledge from the field of radiation epidemiology has a critical impact on cancer management, industry regulations and energy policy. Keywords: Nuclear disasters; long-term consequences of radiation exposure; emergency response EN Nuclear disasters long-term consequences of radiation exposure emergency response 561 568 8 02/28/23 20230301 NES 230301 Introduction One of the most compelling challenges in radiation epidemiology is the scientific evaluation of the long-term health consequences following nuclear radiation disasters. [Extracted from the article]

Published
2023
Full Text
View/download PDF

33. The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in BRCA1/BRCA2/PALB2 -Negative Women.

Author

Larionov, Alexey, Fewings, Eleanor, Redman, James, Goldgraben, Mae, Clark, Graeme, Boice, John, Concannon, Patrick, Bernstein, Jonine, Conti, David V., and Tischkowitz, Marc

Subjects
BREAST tumor risk factors, GENETIC mutation, SEQUENCE analysis, CONFIDENCE intervals, BRCA genes, CASE-control method, RISK assessment, CANCER genes, SECONDARY primary cancer, DESCRIPTIVE statistics, AGE factors in disease, RESEARCH funding, ODDS ratio
Abstract

Simple Summary: As the treatment for breast cancer continues to improve and more women survive their initial diagnosis, there is an increasingly large number of women who are at risk of a second new breast cancer in their lifetimes. However, the hereditary causes of these second breast cancers are not well understood. In this study, we used the latest genetic sequencing technologies to investigate hereditary causes for the second breast cancer in individuals who are known not to have alterations in one of the three main breast cancer genes (BRCA1, BRCA2 and PALB2). We analyzed the genetic profiles of selected participants from the WECARE study, one of the largest studies looking at second breast cancers in women. By comparing the genetic profiles of women who have had one breast cancer to similarly matched women who went on to have a second breast cancer, we found that younger women (under 50) with second breast cancers had a higher number of inherited gene alterations compared with those women with one breast cancer. We did not see the same effect in the older women. The results from this study improve our understanding of the hereditary contribution to second breast cancers. Background: Contralateral breast cancer (CBC) is associated with younger age at first diagnosis, family history and pathogenic germline variants (PGVs) in genes such as BRCA1, BRCA2 and PALB2. However, data regarding genetic factors predisposing to CBC among younger women who are BRCA1/2/PALB2-negative remain limited. Methods: In this nested case-control study, participants negative for BRCA1/2/PALB2 PGVs were selected from the WECARE Study. The burden of PGVs in established breast cancer risk genes was compared in 357 cases with CBC and 366 matched controls with unilateral breast cancer (UBC). The samples were sequenced in two phases. Whole exome sequencing was used in Group 1, 162 CBC and 172 UBC (mean age at diagnosis: 42 years). A targeted panel of genes was used in Group 2, 195 CBC and 194 UBC (mean age at diagnosis: 50 years). Comparisons of PGVs burdens between CBC and UBC were made in these groups, and additional stratified sub-analysis was performed within each group according to the age at diagnosis and the time from first breast cancer (BC). Results: The PGVs burden in Group 1 was significantly higher in CBC than in UBC (p = 0.002, OR = 2.5, 95CI: 1.2–5.6), driven mainly by variants in CHEK2 and ATM. The proportions of PGVs carriers in CBC and UBC in this group were 14.8% and 5.8%, respectively. There was no significant difference in PGVs burden between CBC and UBC in Group 2 (p = 0.4, OR = 1.4, 95CI: 0.7–2.8), with proportions of carriers being 8.7% and 8.2%, respectively. There was a significant association of PGVs in CBC with younger age. Metanalysis combining both groups confirmed the significant association between the burden of PGVs and the risk of CBC (p = 0.006) with the significance driven by the younger cases (Group 1). Conclusion: In younger BRCA1/BRCA2/PALB2-negative women, the aggregated burden of PGVs in breast cancer risk genes was associated with the increased risk of CBC and was inversely proportional to the age at onset. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Germline Mutations in Shelterin Complex Genes Are Associated With Familial Glioma

Author

Bainbridge, Matthew N., Armstrong, Georgina N., Gramatges, M. Monica, Bertuch, Alison A., Jhangiani, Shalini N., Doddapaneni, Harsha, Lewis, Lora, Tombrello, Joseph, Tsavachidis, Spyros, Liu, Yanhong, Jalali, Ali, Plon, Sharon E., Lau, Ching C., Parsons, Donald W., Claus, Elizabeth B., Barnholtz-Sloan, Jill, Il’yasova, Dora, Schildkraut, Joellen, Ali-Osman, Francis, Sadetzki, Siegal, Johansen, Christoffer, Houlston, Richard S., Jenkins, Robert B., Lachance, Daniel, Olson, Sara H., Bernstein, Jonine L., Merrell, Ryan T., Wrensch, Margaret R., Walsh, Kyle M., Davis, Faith G., Lai, Rose, Shete, Sanjay, Aldape, Kenneth, Amos, Christopher I., Thompson, Patricia A., Muzny, Donna M., Gibbs, Richard A., Melin, Beatrice S., and Bondy, Melissa L.

Published
2015
Full Text
View/download PDF

38. The Emergence of Networks in Human Genome Epidemiology: "Challenges and Opportunities"

Author

Seminara, Daniela, Khoury, Muin J., O'Brien, Thomas R., Manolio, Teri, Gwinn, Marta L., Little, Julian, Higgins, Julian P. T., Bernstein, Jonine L., Boffetta, Paolo, Bondy, Melissa, Bray, Molly S., Brenchley, Paul E., Buffler, Patricia A., Casas, Juan Pablo, Chokkalingam, Anand P., Danesh, John, Smith, George Davey, Dolan, Siobhan, Duncan, Ross, Gruis, Nelleke A., Hashibe, Mia, Hunter, David, Jarvelin, Marjo-Riitta, Malmer, Beatrice, Maraganore, Demetrius M., Newton-Bishop, Julia A., Riboli, Elio, Salanti, Georgia, Taioli, Emanuela, Timpson, Nic, Uitterlinden, André G., Vineis, Paolo, Wareham, Nick, Winn, Deborah M., Zimmern, Ron, and Ioannidis, John P. A.

Published
2007
Full Text
View/download PDF

39. The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium

Author

Amirian, E. Susan, Armstrong, Georgina N., Zhou, Renke, Lau, Ching C., Claus, Elizabeth B., Barnholtz-Sloan, Jill S., Ilʼyasova, Dora, Schildkraut, Joellen, Ali-Osman, Francis, Sadetzki, Siegal, Johansen, Christoffer, Houlston, Richard S., Jenkins, Robert B., Lachance, Daniel, Olson, Sara H., Bernstein, Jonine L., Merrell, Ryan T., Wrensch, Margaret R., Davis, Faith G., Lai, Rose, Shete, Sanjay, Amos, Christopher I., Scheurer, Michael E., Aldape, Kenneth, Alafuzoff, Irina, Brännström, Thomas, Broholm, Helle, Collins, Peter, Giannini, Caterina, Rosenblum, Marc, Tihan, Tarik, Melin, Beatrice S., and Bondy, Melissa L.

Published
2016
Full Text
View/download PDF

40. Association of contralateral breast cancer risk with mammographic density defined at higher‐than‐conventional intensity thresholds.

Author

Watt, Gordon P., Knight, Julia A., Nguyen, Tuong L., Reiner, Anne S., Malone, Kathleen E., John, Esther M., Lynch, Charles F., Brooks, Jennifer D., Woods, Meghan, Liang, Xiaolin, Bernstein, Leslie, Pike, Malcolm C., Hopper, John L., and Bernstein, Jonine L.

Subjects
BREAST cancer, DISEASE risk factors, CANCER diagnosis, ODDS ratio, LOGISTIC regression analysis
Abstract

Mammographic dense area (MDA) is an established predictor of future breast cancer risk. Recent studies have found that risk prediction might be improved by redefining MDA in effect at higher‐than‐conventional intensity thresholds. We assessed whether such higher‐intensity MDA measures gave stronger prediction of subsequent contralateral breast cancer (CBC) risk using the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study, a population‐based CBC case‐control study of ≥1 year survivors of unilateral breast cancer diagnosed between 1990 and 2008. Three measures of MDA for the unaffected contralateral breast were made at the conventional intensity threshold ("Cumulus") and at two sequentially higher‐intensity thresholds ("Altocumulus" and "Cirrocumulus") using the CUMULUS software and mammograms taken up to 3 years prior to the first breast cancer diagnosis. The measures were fitted separately and together in multivariable‐adjusted logistic regression models of CBC (252 CBC cases and 271 unilateral breast cancer controls). The strongest association with CBC was MDA defined using the highest intensity threshold, Cirrocumulus (odds ratio per adjusted SD [OPERA] 1.40, 95% CI 1.13‐1.73); and the weakest association was MDA defined at the conventional threshold, Cumulus (1.32, 95% CI 1.05‐1.66). In a model fitting the three measures together, the association of CBC with Cirrocumulus was unchanged (1.40, 95% CI 0.97‐2.05), and the lower brightness measures did not contribute to the CBC model fit. These results suggest that MDA defined at a high‐intensity threshold is a better predictor of CBC risk and has the potential to improve CBC risk stratification beyond conventional MDA measures. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Supplement to: Breast-cancer risk in families with mutations in PALB2.

Author

Antoniou, Antonis C., Casadei, Silvia, Heikkinen, Tuomas, Barrowdale, Daniel, Pylkäs, Katri, Roberts, Jonathan, Lee, Andrew, Subramanian, Deepak, De Leeneer, Kim, Fostira, Florentia, Tomiak, Eva, Neuhausen, Susan L., Teo, Zhi L., Khan, Sofia, Aittomäki, Kristiina, Moilanen, Jukka S., Turnbull, Clare, Seal, Sheila, Mannermaa, Arto, Kallioniemi, Anne, Lindeman, Geoffrey J., Buys, Saundra S., Andrulis, Irene, Radice, Paolo, Tondini, Carlo, Manoukian, Siranoush, Toland, Amanda E., Miron, Penelope, kConFab, Weitzel, Jeffery N., Domchek, Susan, Poppe, Bruce, Claes, Katheen B.M., Yannoukakos, Drakoulis, Concannon, Patrick, Bernstein, Jonine L., James, Paul A., Easton, Douglas, Goldgar, David E., Hopper, John L., Rahman, Nazneen, Peterlongo, Paolo, Nevanlinna, Heli, King, Mary-Claire, Couch, Fergus J, Southey, Melissa C., Winqvist, Robert, Foulkes, William D., and Tischkowitz, Marc

Published
2014

42. Searching for causal relationships of glioma:a phenome-wide Mendelian randomisation study

Author

Saunders, Charlie N., Cornish, Alex J., Kinnersley, Ben, Law, Philip J., Houlston, Richard S., Claus, Elizabeth B., Il’yasova, Dora, Schildkraut, Joellen, Barnholtz-Sloan, Jill S., Olson, Sara H., Bernstein, Jonine L., Lai, Rose K., Chanock, Stephen, Rajaraman, Preetha, Johansen, Christoffer, Jenkins, Robert B., Melin, Beatrice S., Wrensch, Margaret R., Sanson, Marc, and Bondy, Melissa L.

Subjects
Oncology, 0303 health sciences, Cancer Research, medicine.medical_specialty, business.industry, Genome-wide association study, Odds ratio, Phenome, medicine.disease, Phenotype, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, 030220 oncology & carcinogenesis, Glioma, Internal medicine, medicine, Etiology, Mendelian inheritance, symbols, business, 030304 developmental biology, Genetic association
Abstract

Background The aetiology of glioma is poorly understood. Summary data from genome-wide association studies (GWAS) can be used in a Mendelian randomisation (MR) phenome-wide association study (PheWAS) to search for glioma risk factors. Methods We performed an MR-PheWAS analysing 316 phenotypes, proxied by 8387 genetic variants, and summary genetic data from a GWAS of 12,488 glioma cases and 18,169 controls. Causal effects were estimated under a random-effects inverse-variance-weighted (IVW-RE) model, with robust adjusted profile score (MR-RAPS), weighted median and mode-based estimates computed to assess the robustness of findings. Odds ratios per one standard deviation increase in each phenotype were calculated for all glioma, glioblastoma (GBM) and non-GBM tumours. Results No significant associations (P −4) were observed between phenotypes and glioma under the IVW-RE model. Suggestive associations (1.58 × 10−4 P SD = 3.91, P = 9.24 × 10−3) and GBM (ORSD = 4.86, P = 3.23 × 10−2), but the association was primarily driven by the TERT variant rs2736100. Serum low-density lipoprotein cholesterol and plasma HbA1C showed suggestive associations with glioma (ORSD = 1.11, P = 1.39 × 10−2 and ORSD = 1.28, P = 1.73 × 10−2, respectively), both associations being reliant on single genetic variants. Conclusions Our study provides further insight into the aetiological basis of glioma for which published data have been mixed.

Published
2021

43. Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case–control study of contralateral breast cancer risk in the WECARE Study

Author

Brooks, Jennifer D., Teraoka, Sharon N., Bernstein, Leslie, Mellemkjær, Lene, Malone, Kathleen E., Lynch, Charles F., Haile, Robert W., Concannon, Patrick, Reiner, Anne S., Duggan, David J., Schiermeyer, Katherine, Bernstein, Jonine L., Figueiredo, Jane C., and The WECARE Study Collaborative Group

Published
2013
Full Text
View/download PDF

44. Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma

Author

Liu, Yanhong, Melin, Beatrice S., Rajaraman, Preetha, Wang, Zhaoming, Linet, Martha, Shete, Sanjay, Amos, Christopher I., Lau, Ching C., Scheurer, Michael E., Tsavachidis, Spiridon, Armstrong, Georgina N., Houlston, Richard S., Hosking, Fay J., Claus, Elizabeth B., Barnholtz-Sloan, Jill, Lai, Rose, Il’yasova, Dora, Schildkraut, Joellen, Sadetzki, Siegal, Johansen, Christoffer, Bernstein, Jonine L., Olson, Sara H., Jenkins, Robert B., LaChance, Daniel, Vick, Nicholas A., Wrensch, Margaret, Davis, Faith, McCarthy, Bridget J., Andersson, Ulrika, Thompson, Patricia A., Chanock, Stephen, Bondy, Melissa L., and The Gliogene Consortium

Published
2012
Full Text
View/download PDF

47. Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status

Author

Figueiredo, Jane C., Brooks, Jennifer D., Conti, David V., Poynter, Jenny N., Teraoka, Sharon N., Malone, Kathleen E., Bernstein, Leslie, Lee, Won D., Duggan, David J., Siniard, Ashley, Concannon, Patrick, Capanu, Marinela, Lynch, Charles F., Olsen, Jørgen H., Haile, Robert W., and Bernstein, Jonine L.

Published
2011
Full Text
View/download PDF

48. Survey of familial glioma and role of germline p16 INK4A /p14 ARF and p53 mutation

Author

Robertson, Lindsay B., Armstrong, Georgina N., Olver, Bianca D., Lloyd, Amy L., Shete, Sanjay, Lau, Ching, Claus, Elizabeth B., Barnholtz-Sloan, Jill, Lai, Rose, Il’yasova, Dora, Schildkraut, Joellen, Bernstein, Jonine L., Olson, Sara H., Jenkins, Robert B., Yang, Ping, Rynerason, Amanda L., Wrensch, Margaret, McCoy, Lucie, Wienkce, John K., McCarthy, Bridget, Davis, Faith, Vick, Nicholas A., Johansen, Christoffer, Bødtcher, Hanne, Sadetzki, Siegal, Bruchim, Revital Bar-Sade, Yechezkel, Galit Hirsh, Andersson, Ulrika, Melin, Beatrice S., Bondy, Melissa L., and Houlston, Richard S.

Published
2010
Full Text
View/download PDF

49. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer

Author

Reding, Kerryn W., Bernstein, Jonine L., Langholz, Bryan M., Bernstein, Leslie, Haile, Robert W., Begg, Colin B., Lynch, Charles F., Concannon, Patrick, Borg, Ake, Teraoka, Sharon N., Törngren, Therese, Diep, Anh, Xue, Shanyan, Bertelsen, Lisbeth, Liang, Xiaolin, Reiner, Anne S., Capanu, Marinela, Malone, Kathleen E., and The WECARE Collaborative Study Group

Published
2010
Full Text
View/download PDF

50. Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study

Author

Poynter, Jenny N., Langholz, Bryan, Largent, Joan, Mellemkjær, Lene, Bernstein, Leslie, Malone, Kathleen E., Lynch, Charles F., Borg, Åke, Concannon, Patrick, Teraoka, Sharon N., Xue, Shanyan, Diep, Anh T., Törngren, Therese, Begg, Colin B., Capanu, Marinela, Haile, Robert W., Bernstein, Jonine L., and The WECARE Study Collaborative Group

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results